Introduction {#S0001}
============

With its ever-increasing incidence in China, pancreatic cancer is now one of the top 10 tumors associated with cancer-related deaths across the globe.[@CIT0001] In the United States, it is predicted that pancreatic cancer will surpass breast cancer as the second deadliest tumor by 2030.[@CIT0002] According to the 2009 Shanghai Epidemiological Research Statistics report, the incidence of pancreatic cancer in men and women in Shanghai is 17.28/100,000 and 14.04/100,000, respectively.[@CIT0003] According to recent statistics from the National Cancer Center, the incidence of pancreatic cancer in China rose to ninth place in 2015, and the mortality rate places it in sixth place in terms of deaths.[@CIT0002] The annual changes in morbidity and mortality rates are 1.3 and 1.2, respectively, and the overall morbidity and mortality continue to increase every year.[@CIT0001] Pancreatic cancer is currently the most malignant solid tumor with its 5-year survival rate at only about 6%.[@CIT0004],[@CIT0005] Thus, there is a critical need for the identification of novel targets to assist in the development of new surveillance and intervention strategies worldwide. This global interest means that there is a significant amount of novel research being conducted on pancreatic cancer throughout the world.

MicroRNAs (miRNAs) are endogenous non-coding RNA transcripts encoded by various genes, consisting of relatively stable 22 to 23 nucleotides, identified in most peripheral blood and bodily fluids.[@CIT0006]--[@CIT0008] They regulate gene expression by binding to their target mRNA within the 3ʹ-untranslated region (UTR), and are key regulators in a number of cellular functions including cell proliferation, differentiation, metastasis, and apoptosis.[@CIT0006],[@CIT0007],[@CIT0009] Many studies have shown that the expression of some miRNAs is related to the occurrence, development and prognosis of various different types of tumors.[@CIT0007],[@CIT0010] Studies have shown that the combination of miR-887 and miR-3619 can abolish more than 90% of phospholipase D (PLD) enzyme activity, thereby reducing the invasion ability of breast cancer cells.[@CIT0011] Several other studies have shown that miRNA can be used as a biomarker for tumor diagnosis and prognosis.[@CIT0006],[@CIT0012]-[@CIT0015] In addition, Yan Jiang found a significant increase in the level of miR-887-5p in the serum of patients with endometrial cancer, and believed that miR-887-5p in serum may be a potential biomarker for the diagnosis and prognosis of endometrial cancer.[@CIT0007]

StAR-related lipid transfer protein 13 (STARD13), also known as deleted in liver cancer 2 (DLC2) and located on chromosome 13q12.3, is the GTPase-activating protein for Rho and has been shown to act as a tumor suppressor.[@CIT0006],[@CIT0016]-[@CIT0018] It is expressed at low levels in various tumors including lung cancer, kidney cancer, breast cancer and colon tumors.[@CIT0006],[@CIT0019]-[@CIT0021] The ceRNA network moieties associated with STARD13 have been shown to inhibit migration, invasion, and epithelial mesenchymal transformation (EMT) of breast cancer.[@CIT0006],[@CIT0022] STARD13 is targeted by several miRNAs which play key roles in regulating tumor progression.[@CIT0006] MiRNA-125b targets STARD13 and NEU1 to improve the invasion and metastasis of gastric cancer cells,[@CIT0006],[@CIT0023] while in triple-negative breast cancer, miR-9 directly targets STARD13.[@CIT0006],[@CIT0024] Thus, we wanted to evaluate the potential roles of miR-887 and STARD13 in the progression of pancreatic cancers and establish the regulatory relationship between them.

In this study, we investigated the roles of miR-887-3p and STARD13 in the development of pancreatic cancer and studied the regulatory relationship between them.

Patients and Methods {#S0002}
====================

Bioinformatics Analysis {#S0002-S2001}
-----------------------

Genome-wide expression profiling of 118 pancreatic ductal adenocarcinoma (PDAC) samples and 13 control samples, and mRNA expression profiling of 7 pairs of matched pancreatic cancer patient samples were downloaded from the Gene Expression Omnibus (GEO) database ([<https://www.ncbi.nlm.nih.gov/geo/>]{.ul}). GraphPad Prism 8.2.1 was used to analyze the differences in STARD13 expression in normal and pancreatic cancer tissues. Pancreatic cancer patients were divided into two groups based on their expression of STARD13, low STARD13 and high STARD13. Kaplan-Meier (KM) curve analysis was then used to compare the survival rates of these two groups.

Patients and Tissue Samples {#S0002-S2002}
---------------------------

Pancreatic cancer tissues (n = 5) and their adjacent non-tumorous tissues (n = 5) were obtained from the First Affiliated Hospital of College of Medicine, Zhejiang University. After removed from the human body, these tissues were immediately frozen in liquid nitrogen and then stored at −80°C until RNA extraction. Ethical approval for this study was obtained from the Independent Ethics Committee of the First Affiliated Hospital of College of Medicine, Zhejiang University. Informed and written consent was obtained from all patients or their appointed representative in accordance with the ethics committee guidelines.

Cell Lines {#S0002-S2003}
----------

PANC-1 (catalog number: CRL-1469) and HEK293 (catalog number: CRL-1573) were purchased from the American Type Culture Collection (ATCC) (Washington, DC, United States) and cultured in DMEM (GIBCO, catalog number: 11965--092, Shanghai, China) containing 10% fetal bovine serum (FBS) (GIBCO, catalog number: 10091--148, Shanghai, China) and 1% penicillin-streptomycin solution (GIBCO, catalog number: 15070--063, Shanghai, China).

Real-Time Quantitative PCR (RT-qPCR) {#S0002-S2004}
------------------------------------

RNA was extracted from tissue homogenates or cells using Trizol (Ambion, catalog number: 15596--026, Shanghai, China) and reverse transcribed to cDNA using Hiscript Reverse Transcriptase (VAZYME, catalog number: R101-01/02, Nanjing, Jiangsu, China). Reverse transcription of the target miRNA was completed using an hsa-miR-887-3p specific primer and a loop primer ([Table 1](#T0001){ref-type="table"}). This cDNA was then used for RT-qPCR using an SYBR Green Master Mix (VAZYME, catalog number: Q111-02, Nanjing, Jiangsu, China) to determine relative RNA expression. The primers used in this RT-qPCR analysis are shown in [Table 1](#T0001){ref-type="table"}.Table 1Details of the RT-qPCR and Loop PrimersName of PrimersSequence (5ʹ-3ʹ)Gene IDU6-FCGCTTCGGCAGCACATATAC26827U6-RAAATATGGAACGCTTCACGAhsa-miR-887-3p-LoopGTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCTCGGGA100126347hsa-miR-887-3p-FTGCGCGTGAACGGGCGCCATCChsa-miR-887-3p-RCCAGTGCAGGGTCCGAGGTATTGAPDH-FTCAAGAAGGTGGTGAAGCAGG2597GAPDH-RTCAAAGGTGGAGGAGTGGGTSTARD13-FACTGTCTGTGGTGGGAAACA90627STARD13-RTGAGGCACACTTGTTCAACG

Dual-Luciferase Reporter Assays {#S0002-S2005}
-------------------------------

Wild type or mutant copies of the h*STARD13* 3ʹUTR were cloned into a pYr-MirTarget vector (Hunan Changsha Yingrun Biotechnology Co., Ltd., Changsha, Hunan, China), and named STARD13 3ʹUTR-WT and STARD13 3ʹUTR-MUT, respectively. The mutation in the STARD13 3ʹUTR-MUT sequence is shown in red letters in [Figure 1D](#F0001){ref-type="fig"}. HEK293 cells were incubated overnight in 24-well plates at a density of 5 × 10^4^ cells per well. STARD13 3ʹUTR-WT or STARD13 3ʹUTR-MUT were co-transfected into the HEK293 cells with the negative control of miR-887-3p mimic (mimic NC) or miR-887-3p mimic using Lipofectamine 2000 (Invitrogen, catalog number: 11668--019, Shanghai, China) according to the manufacturer's instructions. Dual-luciferase reporter assays (Promega, catalog number: E1910, Beijing, China) were performed 48 h after transfection using the manufacturer's instructions. Differences in transfection efficiency were normalized by dividing the firefly luciferase activity by the values for the Renilla luciferase.Figure 1STARD13 expression is reduced in pancreatic cancer tissues and miR-887-3p regulates STARD13 mRNA. (**A**) GEO data (GEO accession: GSE62165) was used to analyze the expression of STARD13 in normal and PDAC tissues. (**B**) Transcription data from GEO (GEO accession: GSE141873) was used to compare the level of STARD13 in pancreatic cancer and adjacent normal tissues. (**C**) The correlation analysis between STARD13 expression level in patients with pancreatic cancer and overall survival rates was done using KM curves analysis. (**D**) The levels of STARD13 and miR-887-3p in pancreatic cancer tissues and corresponding adjacent normal tissues was evaluated by RT-qPCR. (**E**) Schematic diagram of the STARD13 3ʹUTR point mutation created in this study. (**F**) STARD13 3ʹUTR-WT or STARD13 3ʹUTR-MUT were co-transferred into HEK293 cells with mimic NC or miR-887-3p mimic. The regulatory relationship between miR-887-3p and STARD13 was analyzed using a Dual-luciferase reporter assay system. (**G--H**) Mimic NC, miR-887-3p mimic, the negative control of miR-887-3p inhibitor (inhibitor NC), and miR-887-3p inhibitor were serially transfected into PANC-1 cells. STARD13 (**G**) and miR-887-3p (**H**) expression in these cells was evaluated by RT-qPCR. ANT: adjacent normal tissues; mimic NC: the negative control of miR-887-3p mimic; inhibitor NC: the negative control of miR-887-3p inhibitor; STARD13 3ʹUTR WT: the wild type of STARD13 3ʹ-untranslated region; STARD13 3ʹUTR MUT: the mutant of STARD13 3ʹ-untranslated region; STARD13 3ʹUTR-WT: plasmid expressing the wild type of STARD13 3ʹ-untranslated region was transfected into cells; STARD13 3ʹUTR-MUT: plasmid expressing the mutant of STARD13 3ʹ-untranslated region was transfected into cells; ns, not significant; **\***: *p* \< 0.05; **\*\***: *p* \< 0.01; **\*\*\***: *p* \< 0.001.

Cellular Proliferation Assays {#S0002-S2006}
-----------------------------

PANC-1 cells were cultured overnight in 96-well plates at a density of 5×10^3^ cells per well. MiR-887-3p mimic and inhibitor, and their corresponding negative control was transfected into PANC-1 cells using Lipofectamine 2000. After 48 h, 10 μL of CCK-8 (BIOSHARP, catalog number: BS350B, Beijing, China) was added to each well and the plates were cultured for a further 4 h. The results of this assay were collected by measuring absorbance at OD450 on a microplate reader.

Colony Formation Assays {#S0002-S2007}
-----------------------

PANC-1 cells treated with miR-887-3p mimic or miR-887-3p inhibitor were evenly spread across the 6-well plates, reaching a density of 500 cells per well. After 3 weeks, the culture medium was discarded, and the cells were fixed in 4% formaldehyde. The fixed cells were then stained with Giemsa for 30 min, and photographed using a light microscope and counted.

Cell Cycle Assays {#S0002-S2008}
-----------------

PANC-1 cells were evenly plated and incubated in 6-well plates overnight. After treated with miR-887-3p mimic or miR-887-3p inhibitor for 48 h, the cells were collected and fixed in 70% ethanol at 4°C overnight. After two washes with PBS, the fixed cells were incubated in PBS supplemented with 0.2% Triton X-100 and 10 μg/mL RNase at 37°C for 30 mins. Then, these cells were stained with propidium iodide (PI, 50 μg/mL) (Nanjing kaiji biotechnology development co. LTD, catalog number: KGA512, Nanjing, Jiangsu, China) at 4°C for 30 mins in the dark and analyzed using a flow cytometer.

Apoptosis Assays {#S0002-S2009}
----------------

PANC-1 cells were cultured overnight in 6-well plates at a density of 5×10^5^ cells per well. After treated with miR-887-3p mimic or miR-887-3p inhibitor for 48 h, both adherent and floating cells were collected and washed with PBS. These cells were then stained using Annexin V-FITC and PI (Nanjing kaiji biotechnology development co. LTD, catalog number: KGA108, Nanjing, Jiangsu, China) in the dark for 10 min at room temperature. Subsequent analysis was performed on a flow cytometer. The results are presented as the percentage of apoptotic cells relative to the total number of cells in this analysis.

Transwell Assays {#S0002-S2010}
----------------

After PANC-1 cells were cultured overnight, miR-887-3p mimic and inhibitor, or their corresponding negative control was transfected into PANC-1 cells using Lipofectamine 2000. After 48 h, the cells were used for Transwell analysis. Migration was measured using Matrigel-free transwell plates with an 8 μm porous membrane and invasion was measured using transwell plates with Matrigel. Cells were inoculated into the upper chamber of transwell plates at a density of 4×10^3^ cells per well; 200 μL of serum-free medium was added to the upper chamber and 500 μL of medium supplemented with 10% FBS was added to the lower chamber. After 24 hrs of incubation, cellular migrating or invasion was evaluated using 0.5% crystal violet staining. Images were captured using a light microscope and invasive/motile cells were counted.

Adenovirus Preparation {#S0002-S2011}
----------------------

The miR-887-3p inhibitor was cloned into an adenovirus shuttle vector and co-transfected with the auxiliary packaging plasmid pBHG lox ΔE1,3 Cre (Microbix, Shanghai, China) into HEK293 cells using SunBio Trans-EZ (Shanghai shengbo biomedical technology co., LTD, catalog number: STP07009, Shanghai, China). These cells were used to propagate and prepare adenovirus expressing an inhibitor of miR-887-3p (AV-miR-887-3p inhibitor). At the same time, an empty adenovirus shuttle vector was transfected into HEK293 cells with pBHG lox ΔE1 and 3 Cre, preparing adenovirus expressing the negative control of miR-887-3p inhibitor (AV-Vector). When most of the cells showed typical pathological changes, and 50% of the cells were desiccated, the cells were collected, frozen and thawed three times at −70°C and 37°C and the supernatant was collected as raw viral extract. After virus purification,[@CIT0025] the titer of virus was determined,[@CIT0026] and the virus stored at −70°C.

Animal Experiments {#S0002-S2012}
------------------

Animal studies were performed at the Zhejiang University's animal center. Laboratory animals were used in accordance with the Principles of Laboratory Animal Care (NIH no. 85--23, 1985 version). All experiments using animals were performed in accordance with a protocol approved by the Ethical Committee on Animal Experiments from the Animal Care and Use Committee at Zhejiang University.

Six male SCID mice aged 6--8 weeks were purchased from Beijing Huafukang Biotechnology Co., Ltd., and were housed in pathogen-free transparent plastic cages under a constant 12 hrs light-dark cycle with free access to water and chow. All mice were acclimatized for 1 week prior to the start of the experiment and the mice were euthanized when their single tumor volume reached 1500 mm^3^ and/or they became moribund (weight loss of \>15% of their initial weight, a lack of grooming, cachexia). At the end of the study, all male SCID mice used in this research were placed in the euthanasia chamber, and 100% CO~2~ gas was introduced at a flow rate of 30--70% of the chamber volume per minute. When no corneal reflex, detectable breathing, or heartbeat was observed for more than 5 mins, the animals were confirmed dead. All efforts were made to minimize animal suffering.

To produce the tumor model, 5×10^7^ PANC-1 cells were inoculated subcutaneously into the left chest of each male SCID mouse. Tumor volume was measured every 3 to 4 days after the first week, and six male SCID mice were randomly divided into the AV-Vector group where 1 × 10^9^ PFU AV-Vector was injected into the tail vein twice a week, and the AV-miR-887-3p inhibitor group where 1 × 10^9^ PFU AV-miR-887-3p inhibitor was injected into the tail vein twice a week. After 3 weeks, the mice were euthanized, and the tumor was removed.

Hematoxylin-Eosin (HE) Staining Analysis {#S0002-S2013}
----------------------------------------

Murine tumors were made into paraffin sections.[@CIT0027] After dewaxing the sections were sequentially stained with Mayer's hematoxylin (Sigma, catalog number: H9627, Shanghai, China) and a 1% water-soluble eosin stain (Sinopharm Group, catalog number: 71,014,544, Shanghai, China), magnified under the microscope and then photographed 200 times.

TUNEL Detection Assays {#S0002-S2014}
----------------------

The tumors were placed in paraffin and sectioned as described above. After dewaxing, the sections were sequentially stained using an apoptosis detection kit (Shanghai Yisheng Biotechnology Co., Ltd., catalog number: 40308ES20, Shanghai, China) and DAPI (Beyotime, catalog number: C1002, Shanghai, China), and then photographed as described above.

Statistical Analysis {#S0002-S2015}
--------------------

SPSS 22.0 (IBM SPSS, Armonk, NY, USA) was used for all statistical analyses. Comparisons between two groups were performed using a student's *t* test (unpaired). Comparisons between multiple groups were performed using analysis of variance (ANOVA). *P* \<0.05 indicates a statistically significant difference, and graphs were drawn using GraphPad Prism 8.2.1 (GraphPad Software, Inc., La Jolla, California, United States). Data is representative of at least 3 independent experiments and shown as mean ± standard deviation (SD).

Results {#S0003}
=======

STARD13 Transcription Is Reduced in Pancreatic Cancer Tissues {#S0003-S2001}
-------------------------------------------------------------

Analysis of the GEO data revealed that STARD13 transcription in pancreatic cancer tissues was lower than that of normal tissues ([Figure 1A](#F0001){ref-type="fig"} and [B](#F0001){ref-type="fig"}), and the survival rates of pancreatic cancer patients with low STARD13 transcription levels were lower than those with higher STARD13 levels ([Figure 1C](#F0001){ref-type="fig"}). These observations were confirmed by similarly decreased STARD13 transcription in the pancreatic cancer tissue samples collected during this study ([Figure 1D](#F0001){ref-type="fig"}). These results show that STARD13 mRNA levels decreased in pancreatic cancer tissues, and patients with low levels of STARD13 mRNA had poor prognosis.

MiR-887-3p Regulates the Level of STARD13 mRNA {#S0003-S2002}
----------------------------------------------

The tissue samples we collected were analyzed by RT-qPCR and we found that miR-887-3p expression was higher in pancreatic cancer tissues than in normal tissues ([Figure 1D](#F0001){ref-type="fig"}). Sequence alignment revealed that there is a miR-887-3p recognition sequence in the 3ʹUTR of STARD13 ([Figure 1E](#F0001){ref-type="fig"}). To determine if this is an active regulatory sequence, STARD13 3ʹUTR-WT or STARD13 3ʹUTR-MUT was then co-transfected with miR-887-3p into PANC-1 cells. The dual-luciferase reporter assays revealed that miR-887-3p reduced the expression of STARD13 wild type without affecting the expression of the STARD13 mutant ([Figure 1F](#F0001){ref-type="fig"}), which confirms that miR-887-3p can regulate the expression of STARD13, and revealed the binding site of this regulation. MiR-887-3p mimic and miR-887-3p inhibitor was separately transfected into PANC-1 cells, and STARD13 expression was evaluated using RT-qPCR. This analysis demonstrated that increasing miR-887-3p expression was linked to decreasing STARD13 expression ([Figure 1G](#F0001){ref-type="fig"} and [H](#F0001){ref-type="fig"}). These results indicate that miR-887-3p acts as a negative regulator of STARD13 expression in pancreatic cancer.

MiR-887-3p Promotes the Proliferation and Cell Cycle Process of PANC-1 Cells {#S0003-S2003}
----------------------------------------------------------------------------

MiR-887-3p mimic and miR-887-3p inhibitor and their corresponding controls were transfected into PANC-1 cells. CCK-8, colony formation and cell cycle analyses revealed that the overexpression of miR-887-3p promotes cellular proliferation ([Figure 2A](#F0002){ref-type="fig"}), increases colony formation ([Figure 2B](#F0002){ref-type="fig"} and [2C](#F0002){ref-type="fig"}), and promotes cell cycle process ([Figure 2D](#F0002){ref-type="fig"} and [E](#F0002){ref-type="fig"}). These data suggest that increasing miR-887-3p expression improves the overall proliferation capacity and cell cycle process of pancreatic cancer cells.Figure 2MiR-887-3p promotes the proliferation and cell cycle process of PANC-1 cells. Mimic NC, miR-887-3p mimic, inhibitor NC, and miR-887-3p inhibitor were serially transfected into PANC-1 cells. (**A**) The proliferation of the cells was analyzed using a CCK-8 assay. (**B**) The effect of miR-887-3p on colony formation was examined using a colony formation assay. (**C**) Histogram describing the number of colonies formed under each condition. (**D**) Cell cycle analysis following miR-887-3p treatment in PANC-1 cells. (**E**) Histogram describing the proportion of cells in different stages of the cell cycle under different treatments. Mimic NC: the negative control of miR-887-3p mimic; inhibitor NC: the negative control of miR-887-3p inhibitor; **\***: *p* \< 0.05; **\*\***: *p* \< 0.01; **\*\*\***: *p* \< 0.001.

MiR-887-3 Inhibits Apoptosis, and Promotes Cell Migration and Invasion in PANC-1 Cells {#S0003-S2004}
--------------------------------------------------------------------------------------

PANC-1 cells transfected with miR-887-3p mimic and inhibitor and their relevant controls were subjected to apoptosis and transwell analysis which revealed that the inhibition of miR-887-3p expression improved cellular apoptosis ([Figure 3A](#F0003){ref-type="fig"} and [B](#F0003){ref-type="fig"}) and suppressed cellular migration and invasion ([Figure 3C](#F0003){ref-type="fig"}-[F](#F0003){ref-type="fig"}). Overexpression of miR-887-3p resulted in the opposite effect. These data indicate that increased expression of miR-887-3p may inhibit apoptosis and promote cellular migration and invasion in pancreatic cancer.Figure 3MiR-887-3 inhibits apoptosis, and promotes cellular migration and invasion in PANC-1 cells. Mimic NC, miR-887-3p mimic, inhibitor NC, and miR-887-3p inhibitor were serially transfected into PANC-1 cells. (**A**) Annexin V-FITC and PI staining was used to detect the effect of miR-887-3p on apoptosis. (**B**) Histogram describing the percentage of apoptosis under various treatment conditions. (**C--F**) Transwell analysis was used to examine the effect of miR-887-3p on cellular migration (**C** and **D**) and invasion (**E** and **F**). Mimic NC: the negative control of miR-887-3p mimic; inhibitor NC: the negative control of miR-887-3p inhibitor; **\***: *p* \< 0.05; **\*\***: *p* \< 0.01; **\*\*\***: *p* \< 0.001; **\*\*\*\***: *p* \< 0.0001.

Inhibiting MiR-887-3p Expression Suppresses Tumor Growth and Promotes Apoptosis in vivo {#S0003-S2005}
---------------------------------------------------------------------------------------

We found that miR-887-3p targets STARD13 mRNA and inhibits its expression, thereby promoting the growth, migration, and invasion of pancreatic cancer cells in vitro. We then confirmed these findings in vivo. SCID mice were inoculated with PANC-1 cells and given AV-miR-887-3p inhibitor after tumor formation. We found that treatment with AV-miR-887-3p inhibitor increased the transcription of STARD13 in SCID mice ([Figure 4A](#F0004){ref-type="fig"}) and inhibited tumor growth ([Figure 4B](#F0004){ref-type="fig"} and [C](#F0004){ref-type="fig"}). After tumor removal, HE staining and TUNEL assay revealed that treatment with AV-miR-887-3p inhibitor promoted apoptosis of cells inside the tumor ([Figure 4D](#F0004){ref-type="fig"}-[F](#F0004){ref-type="fig"}). These findings suggest that inhibiting the expression of miR-887-3p increased the expression of STARD13, thereby inhibiting tumor growth and promoting cell apoptosis in pancreatic cancer samples. This suggests that miR-887-3p is a potential target for the treatment of pancreatic cancer.Figure 4In vivo inhibition of miR-887-3p suppresses tumor growth and promotes apoptosis. PANC-1 cells were inoculated subcutaneously into SCID mice. After 1 week, six male SCID mice were randomly divided into two treatment groups AV-Vector Group which was treated with 1 × 10^9^ PFU AV-Vector, and AV-miR-887-3p inhibitor Group which was treated with 1 × 10^9^ PFU AV-miR-887-3p inhibitor. (**A**) After tumor excision, STARD13 transcription was evaluated by RT-qPCR. (**B**) After the tumor was removed, the size of the tumors was measured. (**C**) Statistical curve for tumor volume at different times. (**D**) Images of the tumor tissues after HE staining. (**E**) Images of the tumor tissues after TUNEL staining. (**F**) Histogram of apoptosis rates in the tumor tissues following treatment. AV-Vector: adenovirus expressing the negative control of miR-887-3p inhibitor; AV-miR-887-3p inhibitor: adenovirus expressing an inhibitor of miR-887-3p; **\*\***: *p* \< 0.01; **\*\*\*\***: *p* \< 0.0001.

Discussion {#S0004}
==========

Pancreatic cancer is known as the "king of cancer" and is the most malignant gastrointestinal tumor.[@CIT0028]--[@CIT0030] After diagnosis, the 5-year survival rate of patients is less than 8%.[@CIT0031] Therefore, it is necessary to develop a better understanding of the regulation of pancreatic cancer progression in order to provide novel targets for the diagnosis and treatment of these malignancies. In the current study, we found that in pancreatic cancer, STARD13 is low in expression indicating a poor prognosis, miR-887-3p is highly expressed, and miR-887-3p negatively regulates STARD13. These findings provide direction and basis for further research on miR-887-3p as a target for pancreatic cancer.

MiRNA plays a crucial role in the development and progression of tumors via various complex mechanisms.[@CIT0032],[@CIT0033] Studies have shown that miRNA expression can be used to distinguish normal and cancerous tissues and some specific miRNAs have been found to be closely related to the diagnosis and prognosis of specific cancers.[@CIT0033],[@CIT0034] This means that miRNAs have great potential for application in the diagnosis, prognosis and treatment of various tumors. In our study, we found that miR-887-3p is highly expressed in pancreatic cancer tissues, promoting proliferation, migration, and invasiveness of PANC-1 cells, and tumor growth. Likewise, some researchers have found that the level of miR-887-5p in the serum of patients with endometrial cancer is significantly increased suggesting that serum miR-887-5p levels could be used as a potential biomarker for endometrial cancer.[@CIT0007] In addition, studies have shown that miR-887-3p targets the MDM4 3ʹ-UTR, resulting in reduced expression of MDM4 increasing the risk of small cell lung cancer.[@CIT0035] Whereas, we testified that miR-887-3p targets the STARD13 3ʹ-UTR, leading to decreased STARD13 expression and promoting pancreatic cancer progression. Moreover, STARD13 has been proven to exert inhibitory effects on liver, prostate, lung, breast, kidney, and colon cancers,[@CIT0006],[@CIT0019]-[@CIT0021] which is consistent with those of previous studies.

In breast cancer cells, overexpression of miR-887 can inhibit PLD expression and enzyme activity, thereby reducing the aggressiveness of breast cancer cells.[@CIT0011] Nevertheless, in pancreatic cancer cells, overexpression of miR-887-3p improved cell invasiveness. Furthermore, studies have shown that miR-191-5p and miR-887-3p can only inhibit the expression of MDM4 in small cell lung cancer cells with the C allele rather than A allele.[@CIT0035] These data demonstrate the complexity of the roles of miRNA in cancer and cellular homeostasis. These findings also indicate that miR-887 may play different roles when cooperating with different molecules in different tumor tissues. These also suggest that the details of miR-887-3p's negative regulation of STARD13 to promote pancreatic cancer progression need to be further studied.

In addition, there are some limitations to the study. Only one cell line was used and the expression patterns of miR-887-3p and STARD13 in different pancreatic cell lines were not investigated. Our study is lack of rescue experiments to directly prove the key role of STARD13 in the promotive effects of miR-887-3p on pancreatic cancer cells.

Conclusion {#S0005}
==========

In conclusion, this study found that miR-887-3p promotes pancreatic cancer progression and negatively regulates STARD13. Moreover, STARD13 has been shown to function as a tumor suppressor suggesting that miR-887-3p may promote tumor progression by negatively regulating STARD13 in pancreatic cancer. This finding provides a direction and basis for more extensive analysis of this dynamic and the potential application of miR-887-3p as a diagnostic, prognostic, or therapeutic target in the future.
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